CellaVision ABCVLLY +12.06%69 ROA % is 8.06% as of Mar. 2026, which is 49% below its 10-year median of 15.66. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 857 Medical Devices & Instruments companies, CellaVision AB ranks better than 91.6% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. CellaVision AB's annualizedNet Income for the quarter that ended in Mar. 2026 was $9.66 Mil.
CellaVision AB's average Total Assets over the quarter that ended in Mar. 2026 was $119.80 Mil. Therefore, CellaVision AB's annualized ROA % for the quarter that ended in Mar. 2026 was 8.06%.
The historical rank and industry rank for CellaVision AB's ROA % or its related term are showing as below:
CVLLY'
s ROA % Range Over the Past 10 Years
Min: 12.42 Med: 15.66 Max: 26.34
Current: 12.42
During the past 13 years, CellaVision AB's highest ROA % was 26.34%. The lowest was 12.42%. And the median was 15.66%.
CVLLY's ROA % is ranked better than 91.6% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.59
vs CVLLY: 12.42
CellaVision AB (OTCPK:CVLLY) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
CellaVision AB ROA % Related Terms
CellaVision AB ROA % Historical Data
* Premium members only.
The historical data trend for CellaVision AB's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CellaVision AB's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's ROA % distribution charts can be found below:
* The bar in red indicates where CellaVision AB's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
CellaVision AB (CVLLY) has a ROA % of 8.06% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on CellaVision AB and its competitors. This is 49% below median its historical median of 15.66. Over the past decade, CellaVision AB's ROA % has ranged from 12.42 to 26.34. According to the industry distribution chart, CellaVision AB ranks #72 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 8.4%.
Is CellaVision AB's ROA % too high?
CellaVision AB's current ROA % of 8.06% is 49% below median its 10-year median of 15.66. Over the past 10 years, this metric has ranged from a low of 12.42 to a high of 26.34. The Medical Devices & Instruments industry median ROA % is 0.59. CellaVision AB's value of 8.06% is 1266.1% above this industry median. Based on the distribution chart, CellaVision AB ranks #72 out of 857 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #72 out of 857 companies for ROA %. This places CellaVision AB in the top 8% of its industry — outperforming the majority of peers. The industry median ROA % is 0.59. CellaVision AB's value of 8.06% is 1266.1% above this benchmark. Historically, CellaVision AB's own ROA % has ranged from 12.42 to 26.34 over the past decade. While the company's 10-year median is 15.66 vs. the industry median of 0.59, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.59, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current ROA % of 8.06% is 1266.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current ROA % is 8.06%, which is 49% below median its own 10-year median of 15.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current ROA % is 8.06%, which is 49% below median its 10-year median of 15.66 and 1266.1% above the Medical Devices & Instruments industry median of 0.59. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current ROA % is 8.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
ROA %: 8.06% (49% below median its 10-year median of 15.66)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
Industry Position: 1266.1% above the Medical Devices & Instruments median (#72 of 857)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
